Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1981 Aug;68(2):382–387. doi: 10.1172/JCI110266

Differential effects of two doses of aspirin on platelets-vessel wall introduction in vivo.

K K Wu, Y C Chen, E Fordham, C H Ts'Ao, G Rayudu, D Matayoshi
PMCID: PMC370809  PMID: 6790575

Abstract

Platelet cyclooxygenase appears to be more sensitive to aspirin than the arterial endothelial cell cyclooxygenase. To investigate the dose-related effects of aspirin on platelet-vessel wall interaction in acute vascular injury, male New Zealand White rabbits were treated with either (a) aspirin (150 mg/kg body wt; n = 6), (b) aspirin (30 mg/kg; n = 6), or (c) vehicle (n = 10). After treatment, autologous 111In-platelets were injected and deendothelialization of a 10-cm long segment of abdominal aorta was induced by a balloon catheter. Rabbits were killed 3 h after injury and radioactive counts and percentages of injected radioactivity per gram dry weight of tissue or blood were determined. The 30 mg aspirin group had a significantly lower radioactive count (62.13 +/- SD 6.07 x 10(3) cpm) and percentage of injected radioactivity (0.024 +/- 0.003%) per gram dry weight of damaged aortic tissue than the control (1,167.82 +/- 212.31 x 10(3) cpm/g tissue and 0.435 +/- 0.079%, respectively). By contrast, the 150-mg aspirin group had an elevation of radioactive counts (4,343.12 +/- 556.98 cpm) and percentage (1.632 +/- 0.246%) per gram dry weight of damaged tissue. Infusion of exogenous PGI2 was associated with reduction of lesion radioactivity. These findings were supported by ultrastructural findings. Examined under transmission electron microscopy, the injured aortic wall of 30-mg group was covered throughout the segment by a single layer of platelets without detectable platelet aggregates, while that of the 150-mg group was diffusely packed with multiple layers of platelets. The findings demonstrate that aspirin (30 mg/kg) prevents platelet aggregate formation at the injured arterial wall, whereas 150 mg/kg promotes platelet thrombus formation.

Full text

PDF
382

Images in this article

385Image
on p.385

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aster R. H. Platelet sequestration studies in man. Br J Haematol. 1972 Mar;22(3):259–263. doi: 10.1111/j.1365-2141.1972.tb05671.x. [DOI] [PubMed] [Google Scholar]
  2. Baenziger N. L., Dillender M. J., Majerus P. W. Cultured human skin fibroblasts and arterial cells produce a labile platelet-inhibitory prostaglandin. Biochem Biophys Res Commun. 1977 Sep 9;78(1):294–301. doi: 10.1016/0006-291x(77)91253-0. [DOI] [PubMed] [Google Scholar]
  3. Burch J. W., Baenziger N. L., Stanford N., Majerus P. W. Sensitivity of fatty acid cyclooxygenase from human aorta to acetylation by aspirin. Proc Natl Acad Sci U S A. 1978 Oct;75(10):5181–5184. doi: 10.1073/pnas.75.10.5181. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Davis H. H., Heaton W. A., Siegel B. A., Mathias C. J., Joist J. H., Sherman L. A., Welch M. J. Scintigraphic detection of atherosclerotic lesions and venous thrombi in man by indium-111-labelled autologous platelets. Lancet. 1978 Jun 3;1(8075):1185–1187. doi: 10.1016/s0140-6736(78)90972-8. [DOI] [PubMed] [Google Scholar]
  5. Ellis E. F., Jones P. S., Wright K. F., Richardson D. W., Ellis C. K. Effect of oral aspirin dose on platelet aggregation and arterial prostacyclin synthesis: studies in humans and rabbits. Adv Prostaglandin Thromboxane Res. 1980;6:313–315. [PubMed] [Google Scholar]
  6. Fields W. S., Lemak N. A., Frankowski R. F., Hardy R. J. Controlled trial of aspirin in cerebral ischemia. Stroke. 1977 May-Jun;8(3):301–314. doi: 10.1161/01.str.8.3.301. [DOI] [PubMed] [Google Scholar]
  7. Fuster V., Dewanjee M. K., Kaye M. P., Josa M., Metke M. P., Chesebro J. H. Noninvasive radioisotopic technique for detection of platelet deposition in coronary artery bypass grafts in dogs and its reduction with platelet inhibitors. Circulation. 1979 Dec;60(7):1508–1512. doi: 10.1161/01.cir.60.7.1508. [DOI] [PubMed] [Google Scholar]
  8. Harter H. R., Burch J. W., Majerus P. W., Stanford N., Delmez J. A., Anderson C. B., Weerts C. A. Prevention of thrombosis in patients on hemodialysis by low-dose aspirin. N Engl J Med. 1979 Sep 13;301(11):577–579. doi: 10.1056/NEJM197909133011103. [DOI] [PubMed] [Google Scholar]
  9. Heaton W. A., Davis H. H., Welch M. J., Mathias C. J., Joist J. H., Sherman L. A., Siegel B. A. Indium-III: a new radionuclide label for studying human platelet kinetics. Br J Haematol. 1979 Aug;42(4):613–622. doi: 10.1111/j.1365-2141.1979.tb01174.x. [DOI] [PubMed] [Google Scholar]
  10. Higgs E. A., Moncada S., Vane J. R., Caen J. P., Michel H., Tobelem G. Effect of prostacyclin (PGI2) on platelet adhesion to rabbit arterial subendothelium. Prostaglandins. 1978 Jul;16(1):17–22. doi: 10.1016/0090-6980(78)90197-1. [DOI] [PubMed] [Google Scholar]
  11. Jorgensen L., Packham M. A., Rowsell H. C., Mustard J. F. Deposition of formed elements of blood on the intima and signs of intimal injury in the aorta of rabbit, pig, and man. Lab Invest. 1972 Sep;27(3):341–350. [PubMed] [Google Scholar]
  12. Kelton J. G., Hirsh J., Carter C. J., Buchanan M. R. Thrombogenic effect of high-dose aspirin in rabbits. Relationship to inhibition of vessel wall synthesis of prostaglandin I2-like activity. J Clin Invest. 1978 Oct;62(4):892–895. doi: 10.1172/JCI109203. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Moncada S., Korbut R. Dipyridamole and other phosphodiesterase inhibitors act as antithrombotic agents by potentiating endogenous prostacyclin. Lancet. 1978 Jun 17;1(8077):1286–1289. doi: 10.1016/s0140-6736(78)91269-2. [DOI] [PubMed] [Google Scholar]
  14. Roth G. J., Majerus P. W. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest. 1975 Sep;56(3):624–632. doi: 10.1172/JCI108132. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Scheffel U., McIntyre P. A., Evatt B., Dvornicky J. A., Natarajan T. K., Bolling D. R., Murphy E. A. Evaluation of indium-111 as a new high photon yield gamma-emitting "physiological" platelet label. Johns Hopkins Med J. 1977 Jun;140(6):285–293. [PubMed] [Google Scholar]
  16. Smith J. B., Willis A. L. Aspirin selectively inhibits prostaglandin production in human platelets. Nat New Biol. 1971 Jun 23;231(25):235–237. doi: 10.1038/newbio231235a0. [DOI] [PubMed] [Google Scholar]
  17. Spaet T. H., Stemerman M. B., Veith F. J., Lejnieks I. Intimal injury and regrowth in the rabbit aorta; medial smooth muscle cells as a source of neointima. Circ Res. 1975 Jan;36(1):58–70. doi: 10.1161/01.res.36.1.58. [DOI] [PubMed] [Google Scholar]
  18. TRINDER P. Rapid determination of salicylate in biological fluids. Biochem J. 1954 Jun;57(2):301–303. doi: 10.1042/bj0570301. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Thakur M. L., Welch M. J., Joist J. H., Coleman R. E. Indium-LLL labeled platelets: studies on preparation and evaluation of in vitro and in vivo functions. Thromb Res. 1976 Oct;9(4):345–357. doi: 10.1016/0049-3848(76)90135-3. [DOI] [PubMed] [Google Scholar]
  20. Ts'ao C. H., Glagov S. Platelet adhesion to subendothelial components in experimental aortic injury. Role of fine fibrils and basement membrane. Br J Exp Pathol. 1970 Aug;51(4):423–427. [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES